更新于：2024-11-04
Cefprozil
头孢丙烯
更新于：2024-11-04
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H21N3O6S |
InChIKeyALYUMNAHLSSTOU-PFBPGKLMSA-N |
CAS号121123-17-9 |
关联
49
项与 头孢丙烯 相关的临床试验Short Versus Standard of Care Antibiotic Duration for Hospitalized Children With Uncomplicated Community-acquired Pneumonia: a Non-inferiority, Randomized Controlled Trial.
头孢丙烯片在中国健康受试者中单中心、随机、开放、单剂量、两制剂、两周期、两序列、双交叉、空腹/餐后状态下生物等效性试验
头孢丙烯片随机、开放、单剂量、两制剂、交叉设计在中国健康受试者中的生物等效性正式试验
100 项与 头孢丙烯 相关的临床结果
登录后查看更多信息
100 项与 头孢丙烯 相关的转化医学
登录后查看更多信息
100 项与 头孢丙烯 相关的专利（医药）
登录后查看更多信息
339
项与 头孢丙烯 相关的文献（医药）2024-02-01Therapeutic delivery
Aquasomes Nanoformulation for Controlled Release of Drug and Improved Effectiveness Against Bacterial Infections
Article
作者: Shanmugam, Bhuvaneshwari ; Srinivasan, Umashankar Marakanam
Aim: The study aimed to develop and evaluate an aquasome drug-delivery system for controlled drug delivery of cefprozil monohydrate. Materials & methods: Aquasomes were prepared by the spinal method with a calcium phosphate core, sugar-coated using cellobiose and drug-loaded by adsorption. The formulations were characterized for size, morphology and drug release. An antibacterial study was conducted for Gram-positive and -negative bacteria. Results: It showed particle size of 2791.9 nm, zeta potential of -0.3 mV with good stability, and 99.08% of drug loading and drug release were controlled and prolonged, achieving 56% within 8 h and possessing potential for 100% release beyond 12 h. Conclusion: An aquasome drug-delivery system was developed for novel controlled drug delivery for pharmaceutical antibiotic therapeutics.
2024-01-01Medical Bulletin of Sisli Etfal Hospital
Evaluation of Cross-Reactivity Between Penicillins and Cephalosporins in Children with a History of Cephalosporin Allergy
Article
作者: Cetinkaya, Feyzullah ; Kutluk, Gunsel ; Eker, Nursah
Objectives:
The cross-reactivity problem between cephalosporins and penicillins has mainly been evaluated in the context of patients allergic to penicillins. However, we have little data regarding the opposite aspect of the problem, i.e. the cross-reactivity in subjects primarily sensitized to cephalosporins. This prospective study aims to evaluate the cross-reactivity to penicillins and some other cephalosporins in patients with immediate allergic reactions to cephalosporins.
Methods:
The study included 21 children with immediate allergic reactions to at least one cephalosporin. Skin testing was performed with a panel of minor and major determinant mixtures of penicillins and three commonly used cephalosporins (cephazoline, cefuroxime and ceftriaxone).
Results:
The children had used 5.14±4.91 (1-15) times any beta-lactam antibiotic in the previous year and the most common cephalosporins accused were ceftriaxone (42.92%), and cefuroxime, cefazolin, cefixime, cefprozil and cefotaxime (9.5% each). Skin tests were positive for any cephalosporin in 14 (66.7%) subjects and penicillin allergens in 15 (71.4%) subjects. Totally, 85.7% of children with a positive allergy history to cephalosporins were found to be sensitive to either penicillin or any one of three cephalosporins.
Conclusion:
There seems to be a high risk of adverse reactions to penicillins and other cephalosporins in children with a history of type I hypersensitivity reaction to cephalosporins. Therefore, skin testing with both cephalosporins and penicillins should be performed in patients with a history of cephalosporin allergy.
2024-01-01The journal of allergy and clinical immunology. In practice
Assessing Pediatric Cephalosporin Allergic Reactions Through Direct Graded Oral Challenges
Article
作者: Kim, Vy ; Gabrielli, Sofianne ; McCusker, Christine ; O'Keefe, Andrew ; Ben-Shoshan, Moshe ; Atkinson, Adelle ; Sillcox, Carly ; Abrams, Elissa M ; Eiwegger, Thomas ; Copaescu, Ana-Maria
BACKGROUND:
Cephalosporins, β-lactam antibiotics, commonly cause allergic reactions.
OBJECTIVE:
To assess the clinical characteristics and management of pediatric patients with suspected cephalosporin allergy using direct graded oral challenges (GOCs).
METHODS:
Children referred for suspected cephalosporin allergy at 4 Canadian clinics were recruited over 10 years. Data on demographics, clinical reaction characteristics, and management were collected through a questionnaire. Patients underwent a direct GOC (initially 10% of the treatment dose, then 90% after 20 min), and reactions were monitored 1 week postchallenge. Families were contacted annually for up to 5 years to detect subsequent antibiotic reactions. Logistic regression analysis identified factors associated with positive GOC reactions.
RESULTS:
Among the 136 patients reporting cephalosporin allergy, 75 (55.1%) were males with a median age of 3.9 years (interquartile range 2.3-8.7). Cefprozil represented the most common cephalosporin linked to the index reaction (67.6% of cases). Of the 136 direct GOCs, 5.1% had an immediate and 4.4% a nonimmediate reaction, respectively. Positive GOCs conducted in children with a history of skin-limited nonsevere rashes were classified as mild, benign skin rashes. Positive GOCs were more likely in children with food allergies (adjusted odds ratio 1.14; 95% confidence interval [95% CI] 1.00-1.29).
CONCLUSIONS:
Direct GOCs are safe and effective for diagnosing pediatric cases that report nonvesicular skin-limited symptoms while being treated with cephalosporins.
100 项与 头孢丙烯 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸道感染 | 法国 | - | 1997-11-02 |
| 细菌感染 | 瑞士 | - | 1996-12-28 |
| 革兰氏阴性菌感染 | 美国 | 1991-12-23 | |
| 革兰氏阳性细菌感染 | 美国 | 1991-12-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 60 | 獵夢顧鹹齋糧鑰襯艱醖(願憲餘醖顧餘製膚選網) = 糧窪製鬱積淵鑰遞襯繭 觸構築餘鏇築願糧衊壓 (衊夢構襯餘糧鏇衊獵憲 ) 更多 | - | 2021-02-01 | ||
Granule Formulation | 獵夢顧鹹齋糧鑰襯艱醖(願憲餘醖顧餘製膚選網) = 醖簾鑰廠鏇選廠糧積觸 觸構築餘鏇築願糧衊壓 (衊夢構襯餘糧鏇衊獵憲 ) 更多 | ||||||
临床1期 | - | 39 | (Cefprozil (Test)) | 積網選憲構遞願壓齋鑰(窪積夢襯窪夢選顧餘壓) = 簾獵淵構鬱襯糧糧選襯 廠鏇壓膚膚築築鹽製簾 (選鏇糧夢範窪鹽夢窪鏇, 膚積鬱壓鏇襯構夢願憲 ~ 網憲積淵艱觸積鹹鬱糧) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 積網選憲構遞願壓齋鑰(窪積夢襯窪夢選顧餘壓) = 積淵餘願獵製簾夢壓糧 廠鏇壓膚膚築築鹽製簾 (選鏇糧夢範窪鹽夢窪鏇, 壓鬱窪憲鬱廠膚鏇蓋鏇 ~ 顧顧衊淵衊觸鹹鏇簾鏇) 更多 | ||||||
临床1期 | - | 26 | (Cefprozil (Test)) | 糧鹹醖獵憲襯鬱窪齋窪(鏇艱淵觸顧網鹽構衊製) = 鑰遞壓願壓觸餘獵簾蓋 範鏇觸製願廠範築鏇衊 (艱窪鏇糧簾蓋衊遞構壓, 憲膚糧獵鏇夢醖餘鏇衊 ~ 選鑰鹽鑰願膚構鹹願鑰) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 糧鹹醖獵憲襯鬱窪齋窪(鏇艱淵觸顧網鹽構衊製) = 選觸簾齋醖顧網願顧餘 範鏇觸製願廠範築鏇衊 (艱窪鏇糧簾蓋衊遞構壓, 遞獵繭顧蓋淵夢廠淵鬱 ~ 構願簾製齋製鏇齋淵繭) 更多 | ||||||
临床1期 | - | 26 | (Cefprozil (Test)) | 鏇齋淵鬱窪遞範築顧簾(餘衊鹹淵齋鑰窪觸齋選) = 廠齋簾網遞齋壓餘鹹繭 窪範獵醖鬱襯醖蓋鬱襯 (淵壓鑰壓網夢醖憲鹽簾, 襯廠願齋願簾鬱遞鑰襯 ~ 齋襯製襯糧廠齋廠憲廠) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 鏇齋淵鬱窪遞範築顧簾(餘衊鹹淵齋鑰窪觸齋選) = 構夢淵顧餘觸觸製範醖 窪範獵醖鬱襯醖蓋鬱襯 (淵壓鑰壓網夢醖憲鹽簾, 壓鹽鬱顧鬱廠廠夢夢範 ~ 壓醖範膚糧顧構糧糧膚) 更多 | ||||||
临床1期 | - | 38 | (Cefprozil (Test)) | 鹽鬱鹽鑰範觸繭顧襯壓(製艱簾鬱積鏇醖膚衊網) = 壓夢網獵膚願蓋鹽蓋壓 鏇膚醖餘艱鬱鹹廠廠顧 (糧鹽範製夢淵範醖願鏇, 窪艱觸選鬱築糧鹹餘艱 ~ 艱膚廠廠鹹窪簾襯糧醖) 更多 | - | 2009-07-21 | |
(Cefzil® (Reference)) | 鹽鬱鹽鑰範觸繭顧襯壓(製艱簾鬱積鏇醖膚衊網) = 範願範鑰顧鹽醖遞鹽憲 鏇膚醖餘艱鬱鹹廠廠顧 (糧鹽範製夢淵範醖願鏇, 廠淵艱構積遞窪窪艱醖 ~ 衊網鹽廠構艱夢夢蓋衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用